Medical device data systems and FDA regulation. Should medical device data systems require FDA clearance?
Journal of Healthcare Information Management : JHIM
|August 4, 2010
Summary
Medical Device Data Systems (MDDS) software may soon require FDA clearance due to risks when connected to medical devices. Regulation ensures patient safety and promotes quality management for MDDS vendors.
Area of Science:
- Biomedical Engineering
- Health Informatics
- Regulatory Science
Background:
- Medical devices undergo rigorous FDA regulation, unlike most medical software.
- Medical Device Data Systems (MDDS) are increasingly adopted by hospitals for improved patient care and reduced errors.
- The FDA is evaluating regulatory requirements for MDDS due to potential risks associated with interconnected medical devices.
Purpose of the Study:
- To explore the FDA's proposed regulations for Medical Device Data Systems (MDDS).
- To review the potential risks associated with MDDS when integrated with medical devices.
- To provide a rationale for regulating MDDS and emphasize the need for vendor quality and risk management.
Main Methods:
- Review of current FDA proposals regarding MDDS.
- Analysis of potential risks posed by MDDS in healthcare settings.
- Examination of quality and risk management best practices for MDDS development.
Main Results:
- MDDS offer benefits like increased nursing efficiency and reduced charting errors.
- Interconnection of MDDS with medical devices presents potential risks requiring regulatory oversight.
- Current regulatory frameworks may not adequately address the risks associated with MDDS.
Conclusions:
- MDDS should be subject to FDA regulation to ensure patient safety.
- MDDS vendors must implement robust quality and risk management systems.
- Proactive regulation of MDDS is crucial for safe integration into healthcare systems.
More Related Videos
Related Concept Videos
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Bacterial Signaling
Bacterial signaling can occur within bacteria (intracellular) or between bacteria (intercellular). At times, a group of bacteria behaves like a community. To achieve this, they engage in quorum sensing, the perception of higher cell density that causes changes in gene expression. Quorum sensing involves both extracellular and intracellular signaling. The signaling cascade starts with a molecule called an autoinducer (AI). Individual bacteria produce AIs that move out of the bacterial cell...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

